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Metabolic syndrome (MetS) is a multi-component risk factor for cardiovascular 
disease (CVD) and type 2 diabetes. MetS has been found to be associated with increased risk 
of incident CVD, cardiovascular morbidity and mortality, and prevalence atherosclerosis. 
Cholesterol efflux capacity (CEC) is a measure of the functional property of high-density 
lipoprotein cholesterol (HDL-C). In addition, it characterizes the ability of HDL-C to accept 
cholesterol from extra-hepatic cells in the periphery to the liver and has been shown in 
clinical studies to be inversely associated with atherosclerosis cardiovascular disease 
(ASCVD) and incident cardiovascular disease (CVD) . Low HDL-C is one of the 
components of MetS and it is important to understand how the functionality of HDL captured 
through CEC is affected in MetS. The aim of this study was to evaluate the association 
between CEC and MetS in a multi-ethnic population. In addition, the results obtained based 
on the labeled cholesterol used in the efflux assay were compared for similarities and 
differences. 
A cross-sectional study was performed using data obtained from participants at the 
entry into Dallas Heart Study phase 2 (DHS 2). DHS 2 is a subset of participants from DHS 
 
 
1, a multiethnic probability-based cohort study of Dallas County residents supplemented by 
recruitment of participants’ spouses or significant others. Multivariate regression analyses 
were performed to assess the relationship between CEC and MetS. 
A total of 2942 participants were included in the study. The mean age was 49.4 years. 
A total of 40% of the participants were men and 52% were non-Hispanic Black. CEC 
measured using radiolabeled cholesterol was found to be inversely associated with MetS in 
the unadjusted model (odds ratio per 1-SD 0.86; 95%CI 0.80 – 0.93; P=0.0002). This finding 
remained significant after adjusting for demographics, modifiable risk factors, lipids, post-
menopausal status, and history of cardiovascular disease. CEC measured using fluorescent-
labeled cholesterol was not significantly associated with MetS in the unadjusted model, but 
significant after adjusting for lipids (low-density lipoprotein cholesterol and very low-density 
lipoprotein cholesterol) (adjusted odds ratio per 1-SD 0.82; 95%CI 0.73 – 0.93; P=0.0013).  
There was an inverse relationship between cholesterol efflux capacity, irrespective of 
the labeled cholesterol used in the efflux assay, and metabolic syndrome. With the observed 
association between cholesterol efflux capacity and metabolic syndrome, cholesterol efflux 
capacity can serve as a marker to predict metabolic syndrome and to understand the 
functionality of HDL-C in metabolic syndrome, ultimately allowing for early detection and 
intervention in reducing the risk of cardiovascular disease.  
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BACKGROUND  
Epidemiology of Metabolic Syndrome and Obesity 
Metabolic syndrome (MetS) is a cluster of risk factors that include elevated plasma 
triglyceride, blood pressure, fasting blood glucose, and waist circumference in addition to a 
reduced high-density lipoprotein cholesterol (HDL-C). Based on the 2007 to 2014 National 
Health and Nutrition Examination Survey (NHANES) survey, 34.3% of Americans had 
MetS; however, the prevalence of MetS was unequally distributed among the ethnic groups. 
MetS was lower among non-Hispanic Black males than White males and Mexican-
Americans males while the prevalence was higher among Mexican-Americans females than 
White and Black females.1 Also, the prevalence of MetS has been found to increase with age. 
Metabolic syndrome was found to be present in 19.3% of people 20 to 39 years of age, 
37.7% of people 40 to 59 years of age, and 54.9% of people ≥60 years of age.1  
Obesity is a major driver of MetS2 and its overall age-adjusted prevalence among US 
adults aged ≥20 years was 39.6% (37.9% of males and 41.1% of females).1 The prevalence 
of obesity is higher among non-Hispanic Black females than among non-Hispanic Black 
males and also higher among Hispanic females than among Hispanic males.1 From the 
Behavior Risk Factor Surveillance System (BRFSS) 2014-2016 data, the prevalence of 
obesity was found to be higher among Hispanic adults and non-Hispanic Black adults than 
White adults.1 Although the prevalence of MetS increases with age, the prevalence of obesity 
decreases with age. The prevalence of obesity among middle-aged adults (40-59 years) was 
found to be 40.2% and 37.0% among older adults (≥60 years).1  
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Metabolic Syndrome and Cardiovascular Disease 
MetS is a multicomponent risk factor for Cardiovascular Disease (CVD) and type 2 
diabetes. In several population-based studies (Dallas Heart Study, Framingham, Danish, 
Hoorn, Atherosclerosis Risk in Communities) across the world involving participants who 
were free of CVD and diabetes at baseline, MetS was found to be associated with increased 
risk of incident CVD, cardiovascular morbidity and mortality, and prevalence 
atherosclerosis.3-7 The role of MetS with and without central obesity on incident ischemic 
heart disease was examined among participants enrolled in Singapore Cardiovascular Cohort 
Study that were free of CVD at baseline and followed for an average of 9.6 years. MetS 
either with or without central obesity was found to increase the risk of ischemic heart 
disease.8 
Cholesterol Efflux Capacity 
Cholesterol efflux capacity (CEC) characterizes the ability of HDL-C to accept 
cholesterol from extra-hepatic cells in the periphery, including macrophage-derived foam 
cells in arterial atherosclerotic plaque, to the liver for excretion into the bile as either a free 
cholesterol or bile acids and this pathway is an important early step in anti-atherogenic 
reverse cholesterol transport.9,10  There are several pathways that have been shown to mediate 
cholesterol efflux. These pathways are scavenger receptor class B type 1 (SR-B1), ATP 
binding cassette transporter G1 (ABCG1), ATP binding cassette transporter A1 (ABCA1), 
and aqueous diffusion.11-13  Among these pathways, ABCA1 pathway has been shown to play 
a major role in the maintenance of a normal cholesterol level in tissues. This has been 
demonstrated by the observed accumulation of large amounts of cholesterol in macrophages 
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in mouse models with knocked out ABCA1 gene and in individuals with ABCA1 genetic 
mutations (Tangier disease).14,15  
Cholesterol Efflux Capacity and Metabolic Syndrome 
In the assessment of how the functionality of HDL-C captured through CEC is 
affected in MetS, results from studies have been contradictory in the relationship between 
CEC and MetS. In a study that comprised of patients with personal history of dyslipidemia 
referred to a hospital in Paris, France, the association between clinical and biological features 
of MetS and CEC was investigated. Individual criterion of MetS was associated with CEC 
and there was a statistically significant inverse relation between increased number of MetS 
criteria and CEC independent of other traditional CVD risk factors.16 Among patients with 
untreated MetS, ABCA1 mediated cholesterol efflux was higher, but with no difference in 
ABCG1 mediated cholesterol efflux when compared to a gender and age matched healthy 
controls.17 Another study done in the Netherlands that involved participants free of clinical 
manifestation of CVD, CEC was slightly higher in participants with MetS compared to 
participants without MetS, but this difference was not significant after adjusting for age, sex, 
and diabetes status.18 
In a case-control study, Borja et al explored HDL-apolipoprotein A-I exchange 
(HAE), a measure of HDL function and a key step in reverse cholesterol transport, and 
ABCA1-specific CEC in MetS patients without diabetes and CVD and normolipidemic 
control subjects. HAE and ABCA1-specific CEC were significantly reduced in patients with 
MetS compared to the normolipidemic age and sex matched control subjects.19 In a cross-
sectional study by Annema et al that examined the association of CEC and MetS in a high 
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cardiometabolic risk population of Caucasian origin from the CODAM (Cohort on Diabetes 
and Atherosclerosis Maastricht) cohort. CEC was significantly reduced in patient with MetS 
compared with patient without MetS.20 CEC was also found to be negatively related to MetS 
and this relationship remained significant after adjusting for clinical covariates like age, sex, 
current smoking, alcohol consumption, CVD, glucose lowering drugs, lipid modifying drugs, 
and antihypertensive medication.20 CEC has also been found to be decreased in women with 
polycystic ovarian syndrome compared to health women controls and reduced in all women 
with MetS compared to those without MetS.21 
CEC Measurement Methods and Association with Cardiovascular Events, Risk 
Factors, and HDL-C 
Many studies involving CEC generally use radiolabeled cholesterol efflux assay as 
the standard protocol to measure cholesterol efflux, but this method is not ideal to develop a 
high-throughput assay to assess efflux in a population study involving large number of 
serums.22 An alternative method of efflux measurement is to substitute the radiolabeled 
cholesterol for a fluorescent-labeled cholesterol, which has been shown to provide an 
efficient, rapid, and high-throughput assay to measure efflux in a large number of serums 
from a population study.22 In addition, fluorescent-labeled cholesterol efflux was found to be 
more sensitive for determining ABCA1-mediated efflux than radiolabeled cholesterol efflux 
as ABCA1-mediated efflux has been shown to play a major role in maintenance of a normal 
cholesterol levels in tissues.22  In a study that compared cholesterol efflux using fluorescent-
labeled cholesterol efflux assay with that of radiolabeled cholesterol efflux assay, cholesterol 
efflux measured by fluorescent-labeled cholesterol efflux assay did not significantly correlate 
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with HDL-C while cholesterol efflux measured by radiolabeled cholesterol efflux assay 
correlated significantly with HDL-C (r2 = 0.6, P<0.0001), although both efflux methods 
were significantly correlated with each other.22  
In clinical studies, both CEC measured by fluorescent-labeled cholesterol and 
radiolabeled cholesterol efflux assays have shown consistent findings in their association 
with cardiovascular events, but there are differences in their association with HDL-C and 
other risk factors. Studies from Dallas Heart Study and Guangdong Coronary Artery Disease 
Cohorts used fluorescent-labeled cholesterol efflux assay to measure CEC and showed a 
minimal correlation between CEC and HDL-C (reported correlation coefficients between 
0.07 and 0.3).23,24 EPIC-Norfolk and other studies have used radiolabeled cholesterol efflux 
assay to measure CEC and have shown strong correlation between CEC and HDL-C 
(reported correlation coefficients between 0.1 and 0.8).25-30  
Knowledge Gaps and Public Health Significance 
There are contradictory results regarding the association between CEC and MetS 
from several studies and no study has explored the association in a multi-ethnic population. 
DHS is a multi-ethnic population cohort study that allows for evaluation of clinical 
phenotypes, outcomes, and cardiovascular events in a multi-ethnic population. In addition, 
current studies examining the association between CEC and MetS have used efflux 
determined by radiolabeled cholesterol efflux assay and no study has examined this 
association using efflux determined by fluorescent-labeled cholesterol efflux assay. MetS is a 
multi-component risk factor for cardiovascular disease (CVD) and CEC may serve as a novel 
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biomarker to provide early detection of cardiometabolic risks and modification of CEC 
through developed therapies may help improve these risks. 
Aims 
The aim of this study was to perform a cross-sectional study involving a multi-ethnic 
population to evaluate the association between CEC and MetS. In addition, the results 
obtained based on the labeled cholesterol used in the efflux assay were compared for 
similarities and differences. 
METHODS 
Study Design and Study Population  
The study design is a cross-sectional study involving Dallas Heart Study phase 2 
(DHS2) participants. DHS2 is a longitudinal follow-up study of a subset of participants who 
completed the Dallas Heart Study phase 1 (DHS1), a multiethnic probability-based sample of 
Dallas County adults enrolled between 2000 and 2002 that was weighted to include 
approximately 50% Blacks/African Americans. Recruitment procedures and study design 
have been reported previously.31 A second comprehensive clinical study assessment with 
repeat data collection was done in participants from DHS1 who volunteered between 
September 2007 and December 2009. In addition to DHS1 participants, the DHS2 cohort was 
supplemented by recruitment of participants’ spouses or significant others. The assessments 
done included an extensive health survey, laboratory testing and imaging studies during their 
visit to the University of Texas Southwestern Medical Center. Data and samples were 
collected under the oversight of the institutional review board of the University of Texas 
Southwestern Medical Center. Participants with history of malignancies, history of End Stage 
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Renal Disease (ESRD), and Human Immunodeficiency Virus (HIV) were excluded from this 
study. This study protocol was determined to qualify for exempt status according to 45 CFR 
46.101 (b) by the Committee for the Protection of Human Subjects at the University of Texas 
Health Science Center at Houston. 
Assessment of Demographics, Anthropometric Variables, and Covariates 
Age, sex, race/ethnicity, post-menopausal status, anti-hypertensive medication use, 
statin use, smoking status (current or past smoker), drinking status (current or past drinker) 
and alcohol consumption (grams/week) were self-reported. Height and weight were 
measured using a standard physician’s scale. Body mass index (BMI) was calculated as 
weight in kilograms divided by height in meters squared. Waist circumference was measured 
to the nearest centimeter at the level of the umbilicus. Physical activity was measured using 
Actical (Philips Respironics, Bend, Oregon) physical activity monitor that the participants 
wore on their wrist for 7 days and the monitors were set to record bodily movement, which 
was quantified as an activity count (AC) per minute and moderate to vigorous activity (AC 
>1500 per minute) were recorded.32 Systolic Blood Pressure (SBP) and Diastolic Blood 
Pressure (DBP) were obtained by an average of the third through fifth measurements of 
blood pressures. Fasting concentration of glucose, insulin, and glycated hemoglobin 
(HgbA1c) were determined from venous blood samples. Homeostatic model assessment of 
insulin resistance (HOMA-IR) was calculated using [fasting insulin (μIU/ml) × fasting 
glucose (mmol/liter) /22.5]. Plasma lipids measurements have been described previously.31 
History of diabetes was defined by a fasting glucose level ≥126 mg/dL, non-fasting glucose 
of >200 mg/dL, HbA1c ≥ 6.5% or self-reported history of diabetes in addition to the use of 
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any glucose lowering medication. History of CVD was defined as self-reported or 
adjudicated myocardial infarction, congestive heart failure (CHF)/CHF hospitalization, 
stroke, transient ischemic attack, peripheral revascularization, unstable angina, atrial 
fibrillation, CABG surgery, percutaneous coronary intervention, and other vascular events. 
Assessment of Cholesterol Efflux Capacity and Metabolic Syndrome 
CEC was assessed in vitro using both radiolabeled cholesterol efflux assay and 
fluorescent-labeled cholesterol efflux assay by measuring the efflux of labeled cholesterol 
from J774 macrophages to apolipoprotein B (ApoB)–depleted plasma from study 
participants. These assays evaluate cholesterol efflux as mediated by multiple transports and 
passive diffusion, although fluorescent-labeled cholesterol efflux assay has been shown to be 
more sensitive for ATP-binding cassette transporter A1 (ABCA1)-mediated efflux.22 
Individual efflux values were normalized to values obtained with a pool of 2% apoB-
depleted plasma from selected controls which make the efflux values not to have a specific 
unit. The details of both measurement methods have been described previously.22,33 
MetS, according to the Adult Treatment Panel (ATP) III criteria, was defined as having any 3 
or more of the following criteria: waist circumference >102 cm in men or >89 cm in women; 
triglycerides ≥150 mg/dL; HDL-C <40 mg/dL in men or <50 mg/dL in women; blood 
pressure ≥130/≥85 mmHg; and fasting blood glucose (FBG) ≥100 mg/dL.34 
 
 
9 
 
Statistical Analysis 
CEC was described as both continuous and categorical (based on quartiles) variables. 
MetS was described as categorical variables based on yes/no status and increasing number of 
MetS components (MetS0 = participants without any MetS component; MetS1 = participants 
with 1 MetS component; MetS2 = participants with 2 MetS components; MetS3 = 
participants with 3 MetS components; and MetS4-5 = participants with 4 or 5 MetS 
components).  
Demographic and clinical variables were compared across MetS categorical variables 
using Kruskal-Wallis test for continuous variables and χ2 test for categorical variables. 
Demographic and clinical variables were compared across increasing quartiles of both CEC 
measured by fluorescent-labeled cholesterol efflux assay and CEC measured by radiolabeled 
cholesterol efflux assay using Jonckheere–Terpstra trend test for continuous and categorical 
variables. Categorical variables were presented as frequencies and percentages. Continuous 
variables were presented as means with standard deviations for normally distributed variables 
and medians with interquartile ranges for skewed variables. 
Multivariate logistic regression analyses were performed to assess the association 
between CEC (continuous and quartiles) and MetS status. Multivariate ordinal logistic 
regression analyses using a generalized link function were performed to assess the 
association between CEC (continuous) and increasing component of MetS. Multivariate 
linear regression analyses were performed to assess the association between CEC 
(continuous) and the individual components of MetS (waist circumference, SBP, DBP, 
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triglycerides, HDL-C, and FBG). Covariates were adjusted in five models for logistic 
regression analyses. Model 1 was unadjusted. Model 2 adjusted for demographics (age, sex, 
and race/ethnicity). Model 3 adjusted for modifiable risk factors (physical activity, smoking 
status, and drinking status), in addition to the variables adjusted for in model 2. Model 4 
adjusted for lipids (low-density lipoprotein cholesterol and very low-density lipoprotein 
cholesterol), in addition to the variables adjusted for in model 3. Model 5 adjusted for post-
menopausal status, in addition to the variables adjusted for in model 4. Model 6 adjusted for 
history of CVD, in addition to the variables adjusted for in model 5. For linear regression 
analyses, covariates were adjusted for in one model. Model 1 was unadjusted while model 2 
adjusted for demographics (age, sex, and race/ethnicity) and modifiable risk factors (physical 
activity, smoking status, and drinking status). Non-normally distributed continuous variables 
were log-transformed prior to use in regression analysis. Test for interaction was performed 
to identify effect modification of other covariates such as low-density lipoprotein cholesterol 
(LDL-C), very low-density lipoprotein cholesterol (VLDL-C), gender, ethnicity, obesity, 
history of CVD, and history of DM in the relationship between CEC and MetS. Stratified 
analysis was presented to evaluate the association within each stratum of the interacting 
variables with significant interaction. 
Standardized odds ratios (OR) with 95% confidence intervals (CI) were reported for 
the multivariable binomial and ordinal logistic regression models. Standardized regression 
coefficients (Std β) with 95% confidence intervals (CI) were also reported for linear 
regression models. The standardized measures of association corresponded to the impact of 
1-SD increase in the independent variable on the variability of the dependent variable. Two-
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sided P values <0.05 was considered statistically significant. All statistical analyses were 
performed using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina). 
RESULTS 
Summary of Demographic and Clinical Variables in Study Participants 
A total of 2942 participants were included in the study. The mean age was 49.4 years. 
A total of 40% of the participants were men and 52% were non-Hispanic Black (Table 1). 
For MetS components, mean BMI and waist circumference were 31.1 kg/m2 and 97.2 cm 
respectively; median fasting blood glucose was 94 mg/dL; mean SBP and DBP were 133 
mmHg and 81 mmHg respectively; mean HDL-C was 53 mg/dL; and median triglyceride 
was 102 mg/dL (Table 1). 
Clinical and Biological Variables across MetS Status and Increasing Number of MetS 
Components 
Individuals with MetS were more likely to be older, obese, and females (Table 2). A 
higher proportion of Hispanic had MetS compared with non-Hispanic (16% and 14%, 
P=0.0410; 28% and 32%, P=0.0133, respectively). Individuals with MetS had higher BMI, 
waist circumference, FBG, HgbA1c, insulin, HOMA-IR, SBP, DBP, triglyceride, VLDL-C, 
and lower HDL-C compared to individuals without MetS (Table 2 and Fig. 1). There was no 
significant difference in CEC measured by fluorescent-labeled efflux assay in individuals 
with MetS compared to those without MetS however, individuals without MetS had a 
significantly higher CEC measured by radiolabeled cholesterol efflux assay compared to 
individuals with MetS (absolute difference 0.03; P=0.0002). In addition, physical activity 
was significantly reduced in individuals with MetS compared with those without MetS 
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(absolute difference -10.69; P<0.0001). The prevalence of CVD, diabetes mellitus, 
antihypertensive drug use, and stain use were higher among individuals with MetS compared 
to individuals without MetS. Interestingly, the median alcohol consumption was higher 
among individuals without MetS compared to individuals with MetS (19.1 grams/week and 
7.5 grams/week, respectively; P<0.0001) (Table 2). Individuals who had at least one 
component of MetS were similar to those with MetS (Table 2); however, these results were 
more pronounced among individuals who had between 4-5 MetS components. Individuals 
with no component of MetS had the highest cholesterol efflux capacity measured by 
radiolabeled cholesterol efflux assay and individuals with one component of MetS reported 
higher alcohol consumption compared to individuals in other categories (see Appendix A). 
For the components of MetS, FBG, waist circumference, SBP, DBP, and triglyceride 
increased across increasing number of MetS components while HDL-C decreased across 
increasing number of MetS components (See Appendix A). 
Clinical and Biological Variables across Quartiles of Cholesterol Efflux Capacity 
The proportion of non-Hispanic Black participants was significantly higher in the 
lowest quartile of CEC measured by fluorescent-labeled cholesterol efflux assay compared to 
the highest quartile (56% and 42%, respectively; P=0.0018) (Table 3). Similar result was 
seen in CEC measured by radiolabeled cholesterol efflux assay (54% and 46%, respectively; 
P=0.0003) (Table 4). The proportion of Hispanic participants was significantly higher in the 
highest quartile of CEC measured by fluorescent-labeled cholesterol efflux assay compared 
to Hispanics in the lowest quartile (17.14% and 11.47 %, respectively; P=0.0062) (Table 3). 
In addition, the proportion of non-Hispanic White participants was significantly higher in the 
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highest quartile CEC measured by radiolabeled efflux assay compared to the lowest quartile 
(29% and 36%, respectively; P=0.0007) (Table 4). Individuals in the lowest quartile of CEC 
measured by fluorescent-labeled cholesterol efflux assay had higher BMI, waist 
circumference, insulin and HOMA-IR compared to individuals in the highest quartile while 
individuals in the lowest quartile of CEC measured by radiolabeled cholesterol efflux assay 
had higher BMI, waist circumference, and insulin compared to individuals in the highest 
quartile (Tables 3 and 4). Individuals in the highest quartile of both CEC measured by 
fluorescent-labeled cholesterol efflux and CEC measured by radiolabeled cholesterol efflux 
assays had higher HDL-C, LDL-C, VLDL-C, triglyceride, and median alcohol consumption 
(gram/week) compared to individuals in the lowest quartile (Tables 3 and 4). 
Association between Cholesterol Efflux Capacity and MetS 
In multivariate logistic regression analyses, there was a significant inverse 
relationship between CEC measured by radiolabeled cholesterol efflux assay and MetS in the 
unadjusted model (OR 0.86; 95%CI 0.80 – 0.93; P=0.0002) (Table 6). This finding remained 
significant after adjusting for demographics (age, sex, and ethnicity), modifiable risk factors 
(physical activity, smoking status, and drinking status), lipids (LDL-C and VLDL-C), post-
menopausal status, and history of cardiovascular disease. Also, the association was 
strengthened after adjusting for LDL-C and VLDL-C (adjusted OR, aOR 0.71; 95%CI 0.62 – 
0.80) (Table 6). For CEC measured by fluorescent-labeled cholesterol efflux assay, no 
significant association was found with MetS in the unadjusted model, but significant inverse 
relationship was found after adjusting for demographics (age, sex, and ethnicity), modifiable 
risk factors (physical activity, smoking status, and drinking status), LDL-C, and VLDL-C 
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(aOR, 0.82; 95%CI 0.73 – 0.93; P=0.0013) (Table 5). Similar findings were seen when CEC 
was assessed as quartiles. A significant inverse association between quartiles of CEC 
measured by radiolabeled cholesterol efflux assay and MetS was observed, which was again 
strengthened after adjusting for LDL-C and VLDL-C in model 4 (aOR for second vs. first 
quartile of CEC 0.50; 95%CI 0.36 – 0.71; P<0.0001 and aOR for fourth vs. first quartile of 
CEC 0.38; 95%CI 0.27 – 0.54; P<0.0001) (Table 8). Similar findings were observed in the 
association between CEC measured by fluorescent-labeled cholesterol efflux assay and MetS 
in model 4 (aOR for second vs. first quartile of CEC 0.81; 95%CI 0.58 – 1.13; P=0.2177 and 
aOR for fourth vs. first quartile of CEC 0.54; 95%CI 0.38 – 0.76; P= 0.0005) (Table 7). 
Association between Cholesterol Efflux Capacity and Increasing Number of MetS 
Components 
MetS participants were further categorized based on the number of MetS components 
and the association between CEC measured by fluorescent-labeled cholesterol efflux assay 
and MetS was assessed using multivariate ordinal logistic regression. A significant 
progressive decrease in aOR was observed among participants with increasing number of 
MetS components compared with MetS0, reference category, after adjusting for LDL-C and 
VLDL-C (aOR for MetS3 vs. MetS0 0.78; 95%CI 0.64 – 0.96; P=0.0159 and aOR for 
MetS4-5 vs. MetS0 0.64; 95%CI 0.50 – 0.82; P=0.0003) (Table 9 and Fig. 2). Similar trends 
were observed in the association between CEC measured by radiolabeled efflux assay and 
MetS after adjusting for LDL-C and VLDL-C (aOR for MetS2 vs. MetS0 0.77; 95%CI 0.64 
– 0.92; P=0.0037 and aOR for MetS4-5 vs. MetS0 0.46; 95%CI 0.36 – 0.60; P<0.0001) 
(Table 10 and Fig. 3). 
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Association between Cholesterol Efflux Capacity and Individual MetS Components 
In multivariate linear regression analyses, CEC measured by fluorescent-labeled 
efflux assay was inversely associated with waist circumference (Adjusted Std β = -0.071; 
95%CI -0.108 to -0.035; P=0.0001) and directly associated with log TG (Adjusted Std β = 
0.107; 95%CI 0.071 to 0.143; P<0.0001) and HDL-C (Adjusted Std β = 0.140; 95%CI 0.103 
to 0.176; P<0.0001) (Table 11). These findings remained significant after adjusting for 
demographics and modifiable risk factors. A significant inverse association was found 
between CEC measured by radiolabeled cholesterol efflux assay and waist circumference 
(Adjusted Std β = -0.117; 95%CI -0.154 to -0.080; P < 0.0001) (Table 11). CEC measured by 
radiolabeled cholesterol efflux assay was significantly associated with log TG (Adjusted Std 
β = 0.095; 95%CI 0.058 to 0.132; P< 0.0001), HDL-C (Adjusted Std β = 0.350; 95%CI 
0.315 to 0.384; P<0.0001), and FBG (Adjusted Std β = 0.050; 95%CI 0.013 to 0.088; 
P=0.0078) (Table 11). These associations remained significant after adjusting for 
demographics and modifiable risk factors. CEC radiolabeled was not significantly associated 
with SBP and DBP while CEC fluorescent was not significantly associated with SBD, DBP, 
and FBG.  
Interaction between Cholesterol Efflux Capacity and Covariates in its Relationship with 
MetS 
There was no significant interaction between CEC measured by radiolabeled efflux 
assay and other covariates such as LDL-C, VLDL-C, gender, ethnicity, obesity, history of 
CVD, and history of DM in its relationship with MetS (See Appendix C). There was 
significant interaction between CEC measured by fluorescent efflux assay and history of 
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CVD in its relationship with MetS (P for interaction = 0.03) (See Appendix B). The 
association between CEC measured by fluorescent-cholesterol efflux assay and MetS was 
preserved among those without a hx of CVD but was attenuated among those with a history 
of CVD (Hx CVD: aOR 1.25; 95%CI 0.72 to 2.16; P=0.4284; no hx CVD: aOR 0.79; 95%CI 
0.69 to 0.90; P=0.0001) (See Appendix D). 
 
DISCUSSION 
This cross-sectional study assessed the relationship between cholesterol efflux 
capacity, assessed by measuring the efflux of labeled cholesterol from J774 macrophages to 
apolipoprotein B–depleted plasma using both fluorescent-labeled and radiolabeled 
cholesterol efflux assays, and metabolic syndrome in a multi-ethnic cohort. Cholesterol 
efflux capacity was found to be inversely associated with metabolic syndrome, regardless of 
efflux assay. In addition, there was a significant progressive reduction in cholesterol efflux 
capacity associated with increased number of metabolic syndrome components. Furthermore, 
cholesterol efflux capacity was found to be positively associated with individual components 
of metabolic syndrome such as triglyceride, HDL-C, fasting blood glucose, and negatively 
associated with waist circumference. These findings contradicted the findings from the study 
by Dullaart et al that assessed the ability of plasma from metabolic syndrome subjects to 
promote cholesterol efflux capacity out of a cultured human fibroblast using the radiolabeled 
efflux assay. In their study that involved a total of 170 participants (76 with metabolic 
syndrome and 94 without metabolic syndrome), they concluded that the ability of plasma to 
promote cholesterol efflux out of fibroblast that express abundant ABCA1 is not impaired in 
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individuals with metabolic syndrome despite the presence of low HDL-C.18 The findings 
from this current study also contradicted the findings from Alenezi et al involving 59 subjects 
(22 with metabolic syndrome) that showed that cholesterol efflux capacity using radiolabeled 
cholesterol efflux assay from fibroblasts to plasma of patients with metabolic syndrome was 
not defective.35 The two referenced studies above have similarities as they both used 
fibroblasts and radiolabeled cholesterol efflux assay in determining cholesterol efflux 
capacity and also involved a small sample size. Contrary to the results from these two 
studies, Gall et al demonstrated that cholesterol efflux measured by fluorescent-labeled 
cholesterol efflux assay from human THP-1 macrophages was reduced in 307 individuals 
with metabolic syndrome independent of age, LDL-C, lipid-lowering therapy, smoking 
status, and alcohol consumption.16 The findings from the study by Gall et al were consistent 
with the findings from this current study, which also used macrophages.  
Despite the varying correlations between cholesterol efflux capacity, based on the 
methods of efflux assay, and HDL-C, the associations with metabolic syndrome were similar 
especially after adjusting for VLDL-C. There was strengthening of the association between 
cholesterol efflux capacity and metabolic syndrome after adjusting for VLDL-C, which may 
be partly explained by the fact that triglyceride, one of the components of metabolic 
syndrome, is the main component of VLDL-C and highly correlated with VLDL-C.35 VLDL-
C in this case served as a negative confounder and biased the measure of association of 
cholesterol efflux capacity and metabolic syndrome towards the null. The prevalence of 
metabolic syndrome has been found to be unevenly distributed among ethnic groups1 
however, in this current study there was no difference in the association between cholesterol 
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efflux capacity and metabolic syndrome among ethnic groups and this was also the case for 
gender. 
Several limitations of this study are worth mentioning. First, this is a cross-sectional 
analysis of a large multi-ethnic cohort and the race and ethnic distribution of the study 
sample with oversampling of Blacks do not reflect the general population, which limits the 
generalizability of this study. As expected in observation studies, temporality and causality 
cannot be properly assessed and this is the case in this cross-sectional study. Furthermore, 
there may be sampling bias as the data used for the study was from an existing database with 
voluntary participants who may be different from the general population in terms of health 
status and other important factors. In addition, the effect of multiple testing on statistical 
significance of measure of associations was not accounted for. Lastly, the use of lipid 
lowering, glucose lowering, and anti-hypertensive medications were not adjusted for in the 
multivariable regression analyses, which may be potential confounders. It is worth 
mentioning that the sample size for this study was large as compared to previous studies, 
which provided statistical power to avoid type II error and allowed for further exploration of 
the association of cholesterol efflux capacity and increasing number of metabolic syndrome 
components. In addition, this study included a multi-ethnic cohort and measured cholesterol 
efflux capacity using two different assays. 
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CONCLUSION 
This cross-sectional study demonstrated an inverse relationship between cholesterol 
efflux capacity and metabolic syndrome in a multi-ethnic population. Cholesterol efflux 
capacity was also found to be positively correlated with individual components of metabolic 
syndrome such as HDL-C, triglyceride, fasting blood glucose, and negatively correlated with 
waist circumference. These findings were consistent regardless of the labeled cholesterol 
used in the efflux assay and remained significant after adjusting for demographics, 
modifiable risk factors, lipids, post-menopausal status, and history of cardiovascular disease. 
However, the associations were strengthened after adjustment for VLDL-C. 
Metabolic syndrome is a multicomponent risk factor for cardiovascular disease and it 
has been found to be associated with increased risk of incident cardiovascular disease, 
cardiovascular morbidity and mortality, and prevalence atherosclerosis.3-7 Low HDL-C is one 
of the components of metabolic syndrome and it is important to understand how the function 
of HDL-C is affected in this syndrome. With the observed association between cholesterol 
efflux capacity and metabolic syndrome, cholesterol efflux capacity can serve as a marker to 
predict metabolic syndrome and to understand the functionality of HDL-C in metabolic 
syndrome, ultimately allowing for early detection and intervention in reducing the risk of 
cardiovascular disease.  
It is important to replicate these findings in longitudinal studies to address the issue of 
temporality. Giving that this is the only study till date that assessed the association between 
cholesterol efflux capacity measured by fluorescent-labeled cholesterol efflux assay and 
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metabolic syndrome, additional studies are necessary to replicate the findings from this 
study. 
Table 1:  Overall Demographic and Clinical Variables among Participants 
 
 All Participants (N = 2942) 
Age (year) 49.4 ± 11.1 
Male (%) 40 
Post-menopausal, Female (%) 32 
Race/Ethnicity (%)  
Non-Hispanic Black 52 
Non-Hispanic White 30 
Hispanic 15 
History of CVD (%) 6 
History of DM (%) 16 
Antihypertensive drugs (%) 35 
Statin (%) 17 
Ever Smoked (%) 23 
Alcohol Consumption (grams/week)* 15.0 (2.1, 58.5) 
Alcohol Consumption Status (%)  
Current Drinker 70 
Recent Abstainer 20 
Lifetime Abstainer 9 
Obesity (%) 49 
BMI (kg/m2) 31.1 ± 7.5 
Waist Circumference (cm) 97.2 ± 16.8 
Hip Circumference (cm) 109.2 ± 15.5 
Waist-to-hip Ratio 0.9 ± 0.1 
FBG (mg/dL)* 94 (87, 103) 
Insulin (uIU/mL)* 12.5 (8.2, 19.3) 
HgbA1c (%) 5.8 ± 1.15 
HOMA-IR (Glucose*Insulin / 22.5*18)* 3.0 (1.9, 4.9) 
Physical Activity (Moderate/Vigorous)* 28.5 (13.9, 52.6) 
SBP (mmHg) 132 ± 20 
DBP (mmHg) 81 ± 9 
Cholesterol Efflux Capacity (measured by florescent 
labeled cholesterol) 
0.85 ± 0.24 
Cholesterol Efflux Capacity (measured by 
radiolabeled cholesterol) 
0.94 ± 0.18 
TC (mg/dL) 192 ± 39.62 
TG (mg/dL)* 102 (73, 145) 
VLDL-C (mg/dL)* 20 (15, 29) 
LDL-C (mg/dL) 115 ± 36 
HDL-C (mg/dL) 53 ± 15 
 
 
 
 
 
 
 
Data reported as mean ± SD, median (interquartile range), or percentage. CVD, cardiovascular 
disease; DM, diabetes mellitus; BMI, body mass index; FBG, fasting blood glucose; HgbA1c, 
glycated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; TC; total cholesterol; TG, triglyceride; 
VLDL-C, very low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; 
HDL-C, high-density lipoprotein cholesterol. *Non-normally distributed variable. 
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Table 2: Clinical and Biological Variables in Participants According to Metabolic Syndrome 
Status 
 
 No MetS 
(N = 1823 ) 
MetS 
(N = 1119) 
ǂP Value 
(Two-sided) 
Age (year) 47.7 ± 11.1 52.1 ± 10.7 <0.0001 
Male (%) 42 38 0.0301 
Post-menopausal, Female (%) 27 40 <0.0001 
Race/Ethnicity (%)    
Non-Hispanic Black 51 54 0.1596 
Non-Hispanic White 32 28 0.0133 
Hispanic 14 16 0.0410 
History of CVD (%) 5 14 <0.0001 
History of DM (%) 5 33 <0.0001 
Antihypertensive drugs (%) 22 57 <0.0001 
Statin (%) 11 26 <0.0001 
Ever Smoked (%) 25 21 0.0055 
Alcohol Consumption (grams/week)* 19.1 (3.0, 68.3) 7.5 (1.5, 45.5) <0.0001 
Alcohol Consumption Status (%)    
Current Drinker 74 64 <0.0001 
Recent Abstainer 17.85 24.01 <0.0001 
Lifetime Abstainer 8 12 <0.0001 
Obesity (%) 32 76 <0.0001 
BMI (kg/m2) 28.5 ± 6.3 35.4 ± 7.3 <0.0001 
Waist Circumference (cm) 90.5 ± 14.1 108.0 ± 15.0 <0.0001 
Hip Circumference (cm) 104.4 ± 13.3 117.2 ± 15.6 <0.0001 
Waist-to-hip Ratio 0.9 ± 0.1 0.9 ± 0.1 <0.0001 
FBG (mg/dL)* 91 (85, 96) 103 (94, 119) <0.0001 
Insulin (uIU/mL)* 9.9 (6.85, 14.21) 18.8 (13.1, 27.4) <0.0001 
HgbA1c (%) 5.5 ± 0.8 6.2 ± 1.5 <0.0001 
HOMA-IR (Glucose*Insulin / 22.5*18)* 2.2 (1.5, 3.3) 5.1 (3.3, 8.2) <0.0001 
Physical Activity (Moderate/Vigorous)* 32.8 (16.7, 59.8) 22.1 (10.1, 42.2) <0.0001 
SBP (mmHg) 129 ± 20 139 ± 20 <0.0001 
DBP (mmHg) 80 ± 9 83 ± 9 <0.0001 
Cholesterol Efflux Capacity (measured by 
fluorescent-labeled cholesterol) 
0.85 ± 0.23 0.84 ± 0.25 0.0849 
Cholesterol Efflux Capacity (measured by 
radiolabeled cholesterol) 
0.95 ± 0.17 0.92 ± 0.18 0.0002 
TC (mg/dL) 192 ± 38 193 ± 42 0.9554 
TG (mg/dL)* 87 (65, 116) 138 (98, 190) <0.0001 
VLDL-C (mg/dL)* 17 (13, 23) 27 (20, 38) <0.0001 
LDL-C (mg/dL) 115 ± 34 116 ± 38 0.7974 
HDL-C (mg/dL) 57 ± 15 46 ± 12 <0.0001 
 
Data reported as mean ± SD, median (interquartile range), or percentage. CVD, cardiovascular disease; DM, diabetes mellitus; BMI, body 
mass index; FBG, fasting blood glucose; HgbA1c, glycated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; TC; total cholesterol; TG, triglyceride; VLDL-C, very low-density lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol. *Non-normally distributed variable. 
Bolded values indicate statistical significance. ǂTest for intergroup differences using Kruskal-Wallis test for continuous variables and χ2 for 
categorical variables. 
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Table 3: Clinical and Biological Variables in Participants across Increasing Quartile of 
Cholesterol Efflux Capacity Measured by Fluorescent-Labeled Cholesterol 
 
 Cholesterol Efflux Capacity (Measured by Fluorescent-Labeled Cholesterol) ǂP Value for 
Trend (Two-
sided) 
 Q1 (N=706) Q2 (N=707) Q3 (N=707) Q4 (N=706)  
Age (year) 50.0 ± 10.7 48.6 ± 11.3 48.5 ± 11.1 50.4 ± 11.0 0.0022 
Male (%) 41 39 39 43 0.5834 
Post-menopausal, Female 
(%) 
33 31 32 31 0.5280 
Race/Ethnicity (%)      
Non-Hispanic Black 56 53 51 42 0.0018 
Non-Hispanic White 30 29 31 33 0.2510 
Hispanic 11 15 15 17 0.0062 
History of CVD (%) 10 8 8 8 0.1918 
History of DM (%)  16 15 16 16 0.8531 
Antihypertensive drugs 
(%) 
40 34 34 34 0.0303 
Statin (%) 19 15 17 16 0.2512 
Ever Smoked (%) 23 23 22 24 0.6897 
Alcohol Consumption 
(grams/week)* 
15.0 (2.1, 58.5) 7.5 (1.5, 45.0) 15.0 (2.1, 58.5) 22.5 (3.0, 91.0) <0.0001 
Alcohol Consumption 
Status (%) 
     
Current Drinker 67 67 74 74 0.0012 
Recent Abstainer 23 21 17 19 0.0060 
Lifetime Abstainer 9 11 9 8 0.1972 
Obesity (%) 54 49 50 43 <0.0001 
BMI (kg/m2) 31.8 ± 7.6 31.3 ± 7.4 31.2 ± 7.4 30.0 ± 7.2 <0.0001 
Waist Circumference (cm) 99.0 ± 16.8 97.3 ± 16.4 97.0 ± 17.3 95.1 ± 16.2 0.0002 
Hip Circumference (cm) 110.7 ± 15.3 109.6 ± 15.4 109.2 ± 15.8 107.0 ± 14.8 <0.0001 
Waist-to-hip Ratio 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.5461 
FBG (mg/dL)* 95 (88, 103) 93 (86, 101) 94 (87, 103) 94 (87, 103) 0.2484 
Insulin (uIU/mL)* 13.1 (8.5, 19.8) 12.6 (8.36, 19.96) 12.8 (8.5, 20.3) 11.3 (7.8, 17.3) 0.0003 
HgbA1c (%) 5.8 ± 1.1 5.7 ± 1.1 5.7 ± 1.1 5.8 ± 1.3 0.3196 
HOMA-IR 
(Glucose*Insulin / 
22.5*18)* 
3.1 (1.9, 5.0) 2.9 (1.9, 4.9) 3.0 (1.9, 5.2) 2.7 (1.7, 4.5) 0.0113 
Physical Activity 
(Moderate/Vigorous)* 
27.8 (14.0, 50.0) 28.0 (14.0, 50.7) 28.5 (14.4, 55.0) 28.4 (13.1, 53.5) 0.7666 
SBP (mmHg) 133 ± 20.4 132 ± 20 132 ± 20 133 ± 21 0.2908 
DBP (mmHg) 81 ± 10 81 ± 9 67 ± 10 81 ± 9 0.8193 
Cholesterol Efflux 
Capacity 
0.56 ± 0.11 0.77 ± 0.05 0.92 ± 0.04 1.15 ± 0.16 <0.0001 
TC (mg/dL) 185 ± 38 187 ± 37 195 ± 40 202 ± 39 <0.0001 
TG (mg/dL)* 98 (71, 132) 98 (70, 136) 102 (74, 145) 110 (79, 160) <0.0001 
VLDL-C (mg/dL)* 20 (14, 26) 20 (14, 27) 20 (15, 29) 22 (16, 32) <0.0001 
LDL-C (mg/dL) 113 ± 34 112 ± 35 118 ± 36 119 ± 37 0.0003 
HDL-C (mg/dL) 50 ± 14 52 ± 14 53 ± 16 55 ± 16 <0.0001 
 
Data reported as mean ± SD, median (interquartile range), or percentage. MetS indicates metabolic syndrome. MetS0 = participants without 
any MetS component. MetS1 = participants with 1 MetS component. MetS2 = participants with 2 MetS component. MetS3 = participants 
with 3 MetS component. MetS4-5 = participants with 4 or 5 MetS component. Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, 
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fourth quartile. CVD, cardiovascular disease; DM, diabetes mellitus; BMI, body mass index; FBG, fasting blood glucose; HgbA1c, glycated 
hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
TC; total cholesterol; TG, triglyceride; VLDL-C, very low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; 
HDL-C, high-density lipoprotein cholesterol. *Non-normally distributed variable. Bolded values indicate statistical significance. ǂTest for 
intergroup differences performed using Jonckheere–Terpstra trend test. 
 
Table 4: Clinical and Biological Variables in Participants across Increasing Quartile of 
Cholesterol Efflux Capacity Measured by Radiolabeled Cholesterol 
 
 Cholesterol Efflux Capacity (Measured by Radiolabeled Cholesterol) ǂP Value for 
Trend (Two-
sided) 
 Q1 (N=696) Q2 (N=697) Q3 (N=697) Q4 (N=696)  
Age (year) 50.0 ± 11.40 48.9 ± 11.2 49.9 ± 10.9 50.5 ± 10.5 <0.0001 
Male (%) 44 40 41 36 0.0041 
Post-menopausal, 
Female (%) 
26 31 33 37 <0.0001 
Race/Ethnicity (%)      
Non-Hispanic Black 54 56 50 46 0.0003 
Non-Hispanic White 29 27 31 36 0.0007 
Hispanic 14 14 16 15 0.4458 
History of CVD (%) 10 6 7 9 0.9267 
History of DM (%) 14 15 17 16 0.2347 
Antihypertensive drugs 
(%) 
37 35 33 35 0.3747 
Statin (%) 17 16 16 17 0.9097 
Ever Smoked (%) 23 23 23 24 0.6673 
Alcohol Consumption 
(grams/week)* 
7.5 (1.5, 45.5) 7.5 (1.5, 45.5) 15.0 (2.1, 58.5) 21.0 (3.0, 91.0) <0.0001 
Alcohol Consumption 
Status (%) 
     
Current Drinker 69 69 71 74 0.0225 
Recent Abstainer 21 20 20 19 0.3630 
Lifetime Abstainer 10 11 9 7 0.0209 
Obesity (%) 56 51 47 41 <0.0001 
BMI (kg/m2) 32.3 ± 8.0 31.6 ± 7.5 30.6 ± 7.0 29.6 ± 6.9 <0.0001 
Waist Circumference 
(cm) 
99.5 ± 17.3 97.7 ± 17.2 96.5 ± 15.8 94.3 ± 16.1 <0.0001 
Hip Circumference (cm) 110.9 ± 16.3 109.9 ± 16.0 108.3 ± 14.6 106.9 ± 14.2 <0.0001 
Waist-to-hip Ratio 0.90 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.0038 
FBG (mg/dL)* 94 (87, 102) 93 (86, 102) 94 (87, 105) 94 (87, 102) 0.1886 
Insulin (uIU/mL)* 13.5 (8.8, 21.6) 12.6 (8.6, 19.0) 12.3 (8.1, 18.5) 11.3 (7.7, 17.3) <0.0001 
HgbA1c (%) 5.7 ± 1.0 5.8 ± 1.0 5.8 ± 1.2 5.8 ± 1.3 0.0530 
HOMA-IR 
(Glucose*Insulin / 
22.5*18)* 
3.3 (1.9, 5.4) 2.9 (1.9, 4.7) 2.9 (1.9, 4.9) 2.7 (1.7, 4.5) 0.0007 
Physical Activity 
(Moderate/Vigorous)* 
28.1 (13.4, 50.7) 27.6 (13.7, 52.7) 28.0 (13.9, 51.9) 30.2 (14.5, 53.8) 0.7222 
SBP (mmHg) 131 ± 20 132 ± 20 133 ± 20 133 ± 21 0.5984 
DBP (mmHg) 81 ± 9 81 ± 9 81 ± 9 81 ± 10 0.9364 
Cholesterol Efflux 
Capacity 
0.72±0.10 0.88±0.03 0.99±0.03 1.16±0.11 <0.0001 
TC (mg/dL) 178 ± 37 189 ± 36 197 ± 38 205 ± 40 <0.0001 
TG (mg/dL)* 96 (70, 133) 100 (72, 137) 106 (76, 156) 106 (76, 152) <0.0001 
VLDL-C (mg/dL)* 19 (14, 27) 20 (14, 27) 21 (15, 31) 21 (15, 30) 0.0001 
LDL-C (mg/dL) 110 ± 33 116 ± 34 118 ± 36 119 ± 38 <0.0001 
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HDL-C (mg/dL) 46 ± 13 51 ± 12 54 ± 13 60 ± 18 <0.0001 
Data reported as mean ± SD, median (interquartile range), or percentage. MetS indicates metabolic syndrome. MetS0 = participants without 
any MetS component. MetS1 = participants with 1 MetS component. MetS2 = participants with 2 MetS component. MetS3 = participants 
with 3 MetS component. MetS4-5 = participants with 4 or 5 MetS component. Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, 
fourth quartile. CVD, cardiovascular disease; DM, diabetes mellitus; BMI, body mass index; FBG, fasting blood glucose; HgbA1c, glycated 
hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
TC; total cholesterol; TG, triglyceride; VLDL-C, very low-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; 
HDL-C, high-density lipoprotein cholesterol. *Non-normally distributed variable. Bolded values indicate statistical significance. ǂTest for 
intergroup differences performed using Jonckheere–Terpstra trend test. 
 
Table 5: Results of Multivariate Binomial Logistic Regression Analyses for the Relationship 
between Cholesterol Efflux Capacity Measured by Fluorescent-Labeled Cholesterol and 
Metabolic Syndrome 
 
Model   OR 95% CI P value 
1  0.95 0.88 to 1.03 0.2295 
2 0.94 0.87 to 1.02 0.1358 
3 0.93 0.84 to 1.04 0.2118 
4 0.82 0.73 to 0.93 0.0013 
5 0.82 0.73 to 0.93 0.0013 
6 0.82 0.73 to 0.93 0.0015 
 
OR = odds ratio Model 1 = unadjusted OR; Model 2 = adjusted for demographics (age, sex, and ethnicity); Model 3 = adjusted for variables 
in model 2 + physical activity, smoking status, and drinking status; Model 4 = adjusted for variables in model 3 + lipids (low-density 
lipoprotein cholesterol and very low-density lipoprotein cholesterol); Model 5 = adjusted for variables in model 4 + menopausal status; 
model 6 = adjusted for variables in model 5 + cardiovascular disease history. No MetS as reference group. Bolded values indicate statistical 
significance. 
 
Table 6: Results of Multivariate Binomial Logistic Regression Analyses for the Relationship 
between Cholesterol Efflux Capacity Measured by Radiolabeled Cholesterol and Metabolic 
Syndrome 
 
Model   OR 95% CI P value 
1  0.86 0.80 to 0.93 0.0002 
2  0.82 0.75 to 0.89 <0.0001 
3  0.85 0.76 to 0.95 0.0035 
4  0.71 0.62 to 0.80 <0.0001 
5  0.71 0.62 to 0.80 <0.0001 
6  0.70 0.62 to 0.80 <0.0001 
 
OR = odds ratio. Model 1 = unadjusted OR; Model 2 = adjusted for demographics (age, sex, and ethnicity); Model 3 = adjusted for 
variables in model 2 + physical activity, smoking status, and drinking status; Model 4 = adjusted for variables in model 3 + lipids (low-
density lipoprotein cholesterol and very low-density lipoprotein cholesterol); Model 5 = adjusted for variables in model 4 + menopausal 
status; model 6 = adjusted for variables in model 5 + cardiovascular disease history. No MetS as reference group. Bolded values indicate 
statistical significance. 
 
Table 7: Results of Multivariate Binomial Logistic Regression Analyses for the Relationship 
between Quartiles of Cholesterol Efflux Capacity Measured by Fluorescent-Labeled 
Cholesterol and Metabolic Syndrome 
 
Model Quartiles OR 95% CI P value 
1 Q2 
Q3 
Q4 
0.79 
0.85 
0.79  
0.64 to 0.98 
0.69 to 1.05 
0.64 to 0.98 
0.0317 
0.1364 
0.0290 
2 Q2 0.81 0.65 to 1.01 0.0618 
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Q3 
Q4 
0.89 
0.76  
0.71 to 1.11 
0.61 to 0.95 
0.2925 
0.0139 
3 Q2 
Q3 
Q4 
0.84 
0.73 
0.78 
0.62 to 1.14 
0.54 to 0.98 
0.58 to 1.06 
0.2658 
0.0382 
0.1169 
4 Q2 
Q3 
Q4 
0.81 
0.65 
0.54 
0.58 to 1.13 
0.46 to 0.90 
0.38 to 0.76 
0.2134 
0.0105 
0.0005 
5 Q2 
Q3 
Q4 
0.81 
0.65 
0.54 
0.58 to 1.13 
0.47 to 0.91 
0.38 to 0.76 
0.2177 
0.0113 
0.0005 
6 Q2 
Q3 
Q4 
0.81 
0.65 
0.54 
0.58 to 1.14 
0.47 to 0.91 
0.39 to 0.77 
0.2307 
0.0120 
0.0006 
 
OR = odds ratio. Model 1 = unadjusted OR; Model 2 = adjusted for demographics (age, sex, and ethnicity); Model 3 = adjusted for 
variables in model 2 + physical activity, smoking status, and drinking status; Model 4 = adjusted for variables in model 3 + lipids (low-
density lipoprotein cholesterol and very low-density lipoprotein cholesterol); Model 5 = adjusted for variables in model 4 + menopausal 
status; model 6 = adjusted for variables in model 5 + cardiovascular disease history. No MetS and Q1, first quartile of cholesterol efflux 
capacity, as reference groups. Q2, second quartile; Q3, third quartile; and Q4, fourth quartile. Bolded values indicate statistical significance. 
 
Table 8: Results of Multivariate Binomial Logistic Regression Analyses for the Relationship 
between Quartiles of Cholesterol Efflux Capacity Measured by Radiolabeled Cholesterol and 
Metabolic Syndrome 
 
Model Quartiles OR 95% CI P value 
1 Q2 
Q3 
Q4 
0.65 
0.70 
0.64 
0.52 to 0.81 
0.57 to 0.87 
0.52 to 0.79 
<0.0001 
0.0012 
<0.0001 
2 Q2 
Q3 
Q4 
0.60 
0.63 
0.56 
0.48 to 0.75 
0.50 to 0.78 
0.45 to 0.71 
<0.0001 
<0.0001 
<0.0001 
3 Q2 
Q3 
Q4 
0.60 
0.69 
0.60 
0.44 to 0.81 
0.51 to 0.93 
0.44 to 0.81 
0.0011 
0.0162 
0.0009 
4 Q2 
Q3 
Q4 
0.50 
0.50 
0.38 
0.36 to 0.71 
0.36 to 0.71 
0.27 to 0.54 
<0.0001 
<0.0001 
<0.0001 
5 Q2 
Q3 
Q4 
0.50 
0.50 
0.38 
0.36 to 0.71 
0.36 to 0.71 
0.27 to 0.54 
<0.0001 
<0.0001 
<0.0001 
6 Q2 
Q3 
Q4 
0.52 
0.51 
0.38 
0.37 to 0.73 
0.36 to 0.72 
0.27 to 0.53 
0.0002 
0.0001 
<0.0001 
 
OR = odds ratio. Model 1 = unadjusted OR; Model 2 = adjusted for demographics (age, sex, and ethnicity); Model 3 = adjusted for 
variables in model 2 + physical activity, smoking status, and drinking status; Model 4 = adjusted for variables in model 3 + lipids (low-
density lipoprotein cholesterol and very low-density lipoprotein cholesterol); Model 5 = adjusted for variables in model 4 + menopausal 
status; model 6 = adjusted for variables in model 5 + cardiovascular disease history. No MetS and Q1, first quartile of cholesterol efflux 
capacity, as reference groups. Q2, second quartile; Q3, third quartile; and Q4, fourth quartile. Bolded values indicate statistical significance. 
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Table 9: Results of Multivariate Ordinal Logistic Regression Analyses for the Relationship 
between Cholesterol Efflux Capacity Measured by Fluorescent-Labeled Cholesterol and 
Increasing Number of Metabolic Syndrome Components 
 
Model MetS1  MetS2  MetS3 MetS4-5 
 OR P value 95% 
CI 
OR P value 95% CI OR P value 95% CI OR P value 95% CI 
1 0.92 0.1457 0.81 to 
1.03 
0.93 0.2136 0.83 to 
1.04 
0.91 0.1223 0.80 to 
1.03 
0.89 0.1033 0.77 to 
1.03 
2 0.91 0.1149 0.80 to 
1.02 
0.92 0.1776 0.82 to 
1.04 
0.89 0.0772 0.78 to 
1.01 
0.86 0.0513 0.74 to 
1.00 
3 1.00 0.9315 0.84 to 
1.17 
1.00 0.9954 0.85 to 
1.18 
0.96 0.6370 0.80 to 
1.14 
0.86 0.1697 0.70 to 
1.07 
4 0.93 0.4128 0.78 to 
1.11 
0.90 0.2364 0.75 to 
1.07 
0.78 0.0159 0.64 to 
0.96 
0.64 0.0003 0.50 to 
0.82 
5 0.93 0.4203 0.78 to 
1.11 
0.90 0.2285 0.75 to 
1.07 
0.78 0.0145 0.64 to 
0.95 
0.64 0.0003 0.50 to 
0.82 
6 0.93 0.4246 0.79 to 
1.11 
0.90 0.2378 0.75 to 
1.07 
0.78 0.0157 0.64 to 
0.96 
0.64 0.0003 0.50 to 
0.82 
 
MetS indicates metabolic syndrome. MetS0 = participants without any MetS component. MetS1 = participants with 1 MetS component. 
MetS2 = participants with 2 MetS component. MetS3 = participants with 3 MetS component. MetS4-5 = participants with 4 or 5 MetS 
component. OR = odds ratio. Model 1 = unadjusted OR; Model 2 = adjusted for demographics (age, sex, and ethnicity); Model 3 = adjusted 
for variables in model 2 + physical activity, smoking status, and drinking status; Model 4 = adjusted for variables in model 3 + lipids (low-
density lipoprotein cholesterol and very low-density lipoprotein cholesterol); Model 5 = adjusted for variables in model 4 + menopausal 
status; model 6 = adjusted for variables in model 5 + cardiovascular disease history. MetS0 as reference group. Bolded values indicate 
statistical significance. 
 
Table 10: Results of Multivariate Ordinal Logistic Regression Analyses for the Relationship 
between Cholesterol Efflux Capacity Measured by Radiolabeled Cholesterol and Increasing 
Number of Metabolic Syndrome Components 
 
Model MetS1 MetS2  MetS3  MetS4-5 
 OR P value 95% CI OR P value 95% CI OR P value 95% CI OR P value 95% CI 
1 0.95 0.4312 0.85 to 
1.07 
0.88 0.0324 0.78 to 
0.99 
0.75 <0.0001 0.66 to 
0.85 
0.83 0.0130 0.72 to 
0.96 
2 0.91 0.1259 0.81 to 
1.03 
0.83 0.0029 0.74 to 
0.94 
0.69 <0.0001 0.61 to 
0.79 
0.75 0.0002 0.65 to 
0.88 
3 0.93 0.3695 0.79 to 
1.09 
0.88 0.1220 0.74 to 
1.04 
0.82 0.0251 0.68 to 
0.98 
0.72 0.0029 0.58 to 
0.90 
4 0.85 0.0737 0.72 to 
1.02 
0.77 0.0037 0.64 to 
0.92 
0.62 <0.0001 0.50 to 
0.76 
0.46 <0.0001 0.36 to 
0.60 
5 0.86 0.0826 0.72 to 
1.02 
0.77 0.0041 0.64 to 
0.92 
0.62 <0.0001 0.50 to 
0.76 
0.47 <0.0001 0.36 to 
0.60 
6 0.85 0.0735 0.71 to 
1.02 
0.76 0.0026 0.63 to 
0.91 
0.61 <0.0001 0.50 to 
0.75 
0.46 <0.0001 0.36 to 
0.59 
 
MetS indicates metabolic syndrome. MetS0 = participants without any MetS component. MetS1 = participants with 1 MetS component. 
MetS2 = participants with 2 MetS component. MetS3 = participants with 3 MetS component. MetS4-5 = participants with 4 or 5 MetS 
component. OR = odds ratio. Model 1 = unadjusted OR; Model 2 = adjusted for demographics (age, sex, and ethnicity); Model 3 = adjusted 
for variables in model 2 + physical activity, smoking status, and drinking status; Model 4 = adjusted for variables in model 3 + lipids (low-
density lipoprotein cholesterol and very low-density lipoprotein cholesterol); Model 5 = adjusted for variables in model 4 + menopausal 
status; model 6 = adjusted for variables in model 5 + cardiovascular disease history. MetS0 as reference group. Bolded values indicate 
statistical significance. 
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Table 11: Results of Multivariate Linear Regression Analyses for the Relationship between 
Cholesterol Efflux Capacity Measured by Fluorescent-Labeled Cholesterol and Individual 
Components of Metabolic Syndrome 
 
 Std β 95% CI P value 
Waist Circumference 
Model 1 -0.071  -0.108 to -0.035 0.0001 
Model 2 -0.055 -0.103 to -0.007 0.0238 
SBP 
Model 1 0.016 -0.020 to 0.053 0.3837 
Model 2 0.009 -0.036 to 0.055 0.6873 
DBP 
Model 1 0.006 -0.031 to 0.043 0.7466 
Model 2 0.019 -0.030 to 0.068 0.4534 
logTG 
Model 1 0.107 0.071 to 0.143 <0.0001 
Model 2 0.088 0.040 to 0.136 0.0003 
HDL-C 
Model 1 0.140 0.103 to 0.176 <0.0001 
Model 2 0.124 0.076 to 0.173 <0.0001 
FBG 
Model 1 0.031 -0.006 to 0.068 0.0975 
Model 2 0.029 -0.018 to 0.075 0.2273 
 
Std β = standardized regression coefficient. Model 1 = unadjusted standardized beta; Model 2 = adjusted for demographics (age, sex, and 
ethnicity); and Model 2 = adjusted for demographics (age, sex, and ethnicity) and modifiable risk factors (physical activity, smoking status, 
and drinking status). Bolded values indicate statistical significance. 
 
Table 12: Results of Multivariate Linear Regression Analyses for the Relationship between 
Cholesterol Efflux Capacity Measured by Radiolabeled Cholesterol and Individual 
Components of Metabolic Syndrome 
 
 Std β  95% CI P value 
Waist Circumference    
Model 1 -0.117  -0.154 to -0.080 <0.0001 
Model 2 -0.098 -0.145 to -0.050 <0.0001 
SBP    
Model 1 0.027 -0.010 to 0.064 0.1504 
Model 2 0.023 -0.022 to 0.068 0.3182 
DBP    
Model 1 -0.005 -0.042 to 0.033 0.8120 
Model 2 0.027 -0.022 to 0.076 0.2800 
logTG    
Model 1 0.095 0.058 to 0.132 <0.0001 
Model 2 0.097 0.049 to 0.145 <0.0001 
HDL-C    
Model 1 0.350 0.315 to 0.384 <0.0001 
Model 2 0.357 0.312 to 0.403 <0.0001 
FBG    
Model 1 0.050 0.013 to 0.088 0.0078 
Model 2 0.077 0.030 to 0.123 0.0013 
 
Std β = standardized regression coefficient. Model 1 = unadjusted standardized beta; Model 2 = adjusted for demographics (age, sex, and 
ethnicity); and Model 2 = adjusted for demographics (age, sex, and ethnicity) and modifiable risk factors (physical activity, smoking status, 
and drinking status). Bolded values indicate statistical significance. 
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Figure 1: Individual Components of Metabolic Syndrome across Increasing Number of 
Metabolic Syndrome Components 
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FBG = Fasting blood glucose, WC = waist circumference, SBP = systolic blood pressure, 
DBP = diastolic blood pressure, TG = triglyceride, and HDL-C = high-density lipoprotein. 
Mean ± SD reported for WC, SBP, DBP, and HDL-C. Median (interquartile range) reported 
for FBG. MetS indicates metabolic syndrome. MetS0 = participants without any MetS 
component. MetS1 = participants with 1 MetS component. MetS2 = participants with 2 
MetS component. MetS3 = participants with 3 MetS component. MetS4-5 = participants 
with 4 or 5 MetS component. Statistical significance was determined by performing two-
tailed, Jonckheere–Terpstra trend test (**** P < 0.0001). 
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Figure 2: Relationship between Cholesterol Efflux Capacity Measured by Fluorescent-
Labeled Cholesterol and Increasing Number of Metabolic Syndrome Components 
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Model 1 = unadjusted OR. Model 4 = adjusted for demographics (age, sex, and ethnicity) + modifiable risk factors (physical activity, 
smoking status, and drinking status) + lipid (low-density lipoprotein cholesterol and very low-density lipoprotein cholesterol). MetS0 = 
participants without any MetS component. MetS1 = participants with 1 MetS component. MetS2 = participants with 2 MetS component. 
MetS3 = participants with 3 MetS component. MetS4-5 = participants with 4 or 5 MetS component. MetS indicates metabolic syndrome. 
MetS0 as reference group. 
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Figure 3: Relationship between Cholesterol Efflux Capacity Measured by Radiolabeled 
Cholesterol and Increasing Number of Metabolic Syndrome Components 
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Model 1 = unadjusted OR. Model 4 = adjusted for demographics (age, sex, and ethnicity) + modifiable risk factors (physical activity, 
smoking status, and drinking status) + lipid (low-density lipoprotein cholesterol and very low-density lipoprotein cholesterol). MetS0 = 
participants without any MetS component. MetS1 = participants with 1 MetS component. MetS2 = participants with 2 MetS component. 
MetS3 = participants with 3 MetS component. MetS4-5 = participants with 4 or 5 MetS component. MetS indicates metabolic syndrome. 
MetS0 as reference group. 
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APPENDICES 
 
Appendix A: Clinical and Biological Variables among Participants According to Increasing 
Number of Metabolic Syndrome Components 
 
 Number of MetS Criteria ǂP Value for 
Trend (Two-
sided) 
 MetS0 (N = 
460) 
MetS1 (N = 
707) 
MetS2 (N = 
792) 
MetS3 (N = 
575 ) 
MetS4-5 (N 
= 340) 
 
Age (year) 44.4 ± 10.7 49.2 ± 11.0 50.2 ± 10.9 50.9 ± 10.9 52.6 ± 10.1 <0.0001 
Male (%) 42 42 40 40 35 0.0352 
Post-menopausal, Female (%) 21 30 33 36 43 <.0001 
Race/Ethnicity (%)       
Non-Hispanic Black 44 51 56 56 49 0.0039 
Non-Hispanic White 39 33 28 25 28 <.0001 
Hispanic 15 13 13 17 19 0.0103 
History of CVD (%) 2 7 9 13 13 <0.0001 
History of DM (%) 1 4 14 27 45 <0.0001 
Antihypertensive drugs (%) 11 25 39 51 56 <0.0001 
Statin (%) 9 14 16 24 24 <0.0001 
Ever Smoked (%) 23 28 22 22 22 0.0565 
Alcohol Consumption 
(grams/week)* 
19.5 (3.0, 
58.5) 
22.5 (3.0, 
91.0) 
9.0 (1.5, 
45.5) 
7.5 (1.5, 
58.5) 
10.6 (1.5, 
58.5) 
0.0006 
Alcohol Consumption Status 
(%) 
      
Current Drinker 77 74 71 66 60 <0.0001 
Recent Abstainer 17 17 22 22 25 <0.0001 
Lifetime Abstainer 6 10 8 12 15 <0.0001 
Obesity (%) 7 28 56 78 82 <0.0001 
BMI (kg/m2) 25.0 ± 3.4 27.7 ± 5.4 32.3 ± 7.0 35.4 ± 7.3 36.2 ± 6.6 <0.0001 
Waist Circumference (cm) 82.0 ± 9.1 88.9 ± 12.2 100.0 ± 
15.0 
107.8 ± 14.9 110.3 ± 14.1 <0.0001 
Hip Circumference (cm) 97.9 ± 7.8 102.8 ± 12.0 111.6 ± 
15.0 
117.3 ± 15.8 118.3 ± 14.5 <0.0001 
Waist-to-hip Ratio 0.8 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 <0.0001 
FBG (mg/dL)* 88 (83, 93) 90 (85, 95) 94 (88, 
101) 
101 (91, 
113) 
110 (102, 
139) 
<0.0001 
Insulin (uIU/mL)* 7.7 (5.4, 
10.3) 
9.6 (6.8, 
13.4) 
13.4 (9.3, 
18.6) 
17.9 (12.8, 
26.2) 
21.4 (14.5, 
30.4) 
<0.0001 
HgbA1c (%) 5.3 ± 0.3 5.4 ± 0.5 5.8 ± 1.1 6.1 ± 1.3 6.6 ± 1.7 <0.0001 
HOMA-IR (Glucose*Insulin / 
22.5*18)* 
1.6 (1.1, 
2.3) 
2.2 (1.5, 3.1) 3.2 (2.2, 
4.5) 
4.8 (3.2, 7.3) 6.4 (4.3, 
10.1) 
<0.0001 
Physical Activity 
(Moderate/Vigorous)* 
39.5 (21.0, 
65.0) 
30.2 (16.1, 
55.6) 
28.0 (13.4, 
54.0) 
23.4 (11.1, 
43.6) 
21.9 (9.8, 
41.1) 
<0.0001 
SBP (mmHg) 115 ± 8 130 ± 19 136 ± 20 138 ± 20 145 ± 19 <0.0001 
DBP (mmHg) 74 ± 6 80 ± 9 83 ± 9 83 ± 10 85 ± 9 <0.0001 
Cholesterol Efflux Capacity 
(Fluorescent method) 
0.87 ± 0.23 0.85 ± 0.23 0.85 ± 0.23 0.84 ± 0.26 0.84 ± 0.26 0.0588 
Cholesterol Efflux Capacity 
(Radiolabeled method) 
0.96 ± 0.18 0.95 ± 0.17 0.94 ± 0.17 0.91 ± 0.18 0.93 ± 0.17 <0.0001 
TC (mg/dL) 186 ± 34 192 ± 38 193 ± 39 194 ± 43 198 ± 43 0.0005 
TG (mg/dL)* 74 (59, 97) 87 (66, 115) 100 (75, 
135) 
125 (92, 
171) 
178 (151, 
234) 
<0.0001 
VLDL-C (mg/dL)* 15 (12, 19) 17 (13, 23) 20 (15, 27) 25 (18, 34) 36 (30, 46) <0.0001 
LDL-C (mg/dL) 109 ± 32 115 ± 34 117 ± 35 119 ± 38 116 ± 41 <0.0001 
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HDL-C (mg/dL) 62 ± 14 57 ± 15 53 ± 15 46 ± 12 41 ± 9 <0.0001 
Data reported as mean ± SD, median (interquartile range), or percentage. MetS0 = participants without any MetS component. MetS1 = 
participants with 1 MetS component. MetS2 = participants with 2 MetS component. MetS3 = participants with 3 MetS component. MetS4-5 
= participants with 4 or 5 MetS component. CVD, cardiovascular disease; DM, diabetes mellitus; BMI, body mass index; FBG, fasting 
blood glucose; HgbA1c, glycated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; TC; total cholesterol; TG, triglyceride; VLDL-C, very low-density lipoprotein cholesterol; LDL-C, 
low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol. *Non-normally distributed variable. Bolded values 
indicate statistical significance. ǂTest for intergroup differences performed using Jonckheere–Terpstra trend test. 
 
Appendix B: Results of Test for Interaction between Cholesterol Efflux Capacity Measured 
by Fluorescent-Labeled Cholesterol and Other Covariates in its Relationship with Metabolic 
Syndrome 
 P valueǂ 
CEC x LDL-C 0.3216 
CEC x VLDL-C 0.5754 
CEC x Male 0.0601 
CEC x Black 0.9613 
CEC x History of CVD 0.0304 
CEC x History of DM 0.2856 
 
 
 
 
 
 
Appendix C: Results of Test for Interaction between Cholesterol Efflux Capacity Measured 
by Radiolabeled Cholesterol and Other Covariates in its Relationship with Metabolic 
Syndrome 
 P valueǂ 
CEC x LDL-C 0.2248 
CEC x VLDL-C 0.3354 
CEC x Male 0.1168 
CEC x Black 0.7511 
CEC x History of CVD 0.7107 
CEC x History of DM 0.9740 
 
 
 
 
 
 
 
CEC, cholesterol efflux capacity measured by radiolabeled 
cholesterol. LDL-C, low-density lipoprotein cholesterol; VLDL-
C, very low-density lipoprotein cholesterol; CVD, cardiovascular 
disease; and DM, diabetes mellitus. ǂAdjusted for demographics 
(age, sex, and ethnicity), modifiable risk factors (physical 
activity, smoking status, and drinking status), lipids (LDL-C and 
VLDL-C), post-menopausal status, and history of CVD. 
 
CEC, cholesterol efflux capacity measured by fluorescent-labeled 
cholesterol. LDL-C, low-density lipoprotein cholesterol; VLDL-
C, very low-density lipoprotein cholesterol; CVD, cardiovascular 
disease; and DM, diabetes mellitus. ǂAdjusted for demographics 
(age, sex, and ethnicity), modifiable risk factors (physical 
activity, smoking status, and drinking status), lipids (LDL-C and 
VLDL-C), post-menopausal status, and history of CVD. 
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Appendix D: Relationship between Cholesterol Efflux Capacity Measured by Fluorescent-
Labeled Cholesterol and Metabolic Syndrome within Cardiovascular History Strata  
 
0.1 1 10
Overall (1537/2942)
No History of CVD (1431/2942)
History of CVD (237/2942)
Odds Ratioǂ (95% CI)
0.82 (0.73, 0.93)
0.79  (0.69, 0.90)
1.25  (0.72, 2.16)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Odds ratio reported separately for participants with and without history of 
cardiovascular. Bolded values indicate statistical significance. ǂOdds ratio adjusted 
for demographics (age, sex, and ethnicity), modifiable risk factors (physical 
activity, smoking status, and drinking status), lipids (low-density lipoprotein 
cholesterol and very low-density lipoprotein cholesterol), post-menopausal status, 
and history of CVD. 
 
34 
 
REFERENCES 
1. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: 
A report from the american heart association. Circulation. 2019;139(10):e56-e66. 
2. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol 
Metab. 2004;89(6):2595-2600. 
3. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a 
precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 
2005;112(20):3066-3072. 
4. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin 
resistance, the metabolic syndrome, and risk of incident cardiovascular disease: A 
population-based study. J Am Coll Cardiol. 2007;49(21):2112-2119. 
5. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk 
of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes 
Care. 2005;28(2):385-390. 
6. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the 
metabolic syndrome for long term prediction of total and cardiovascular mortality: 
Prospective, population based cohort study. BMJ. 2006;332(7546):878-882. 
 
35 
 
7. Chen K, Lindsey JB, Khera A, et al. Independent associations between metabolic 
syndrome, diabetes mellitus and atherosclerosis: Observations from the dallas heart study. 
Diab Vasc Dis Res. 2008;5(2):96-101. 
8. Lee J, Ma S, Heng D, et al. Should central obesity be an optional or essential component 
of the metabolic syndrome? ischemic heart disease risk in the singapore cardiovascular 
cohort study. Diabetes Care. 2007;30(2):343-347. 
9. Rosenson RS, Brewer HB,Jr, Davidson WS, et al. Cholesterol efflux and atheroprotection: 
Advancing the concept of reverse cholesterol transport. Circulation. 2012;125(15):1905-
1919. 
10. Talbot CPJ, Plat J, Ritsch A, Mensink RP. Determinants of cholesterol efflux capacity in 
humans. Prog Lipid Res. 2018;69:21-32. 
11. Adorni MP, Zimetti F, Billheimer JT, et al. The roles of different pathways in the release 
of cholesterol from macrophages. J Lipid Res. 2007;48(11):2453-2462. 
12. Zhao Y, Van Berkel TJ, Van Eck M. Relative roles of various efflux pathways in net 
cholesterol efflux from macrophage foam cells in atherosclerotic lesions. Curr Opin Lipidol. 
2010;21(5):441-453. 
13. Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-
BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 
2007;117(8):2216-2224. 
 
36 
 
14. Francone OL, Royer L, Boucher G, et al. Increased cholesterol deposition, expression of 
scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages. 
Arterioscler Thromb Vasc Biol. 2005;25(6):1198-1205. 
15. Oram JF. Tangier disease and ABCA1. Biochim Biophys Acta. 2000;1529(1-3):321-330. 
16. Gall J, Frisdal E, Bittar R, et al. Association of cholesterol efflux capacity with clinical 
features of metabolic syndrome: Relevance to atherosclerosis. J Am Heart Assoc. 
2016;5(12):10.1161/JAHA.116.004808. 
17. Lucero D, Sviridov D, Freeman L, et al. Increased cholesterol efflux capacity in 
metabolic syndrome: Relation with qualitative alterations in HDL and LCAT. 
Atherosclerosis. 2015;242(1):236-242. 
18. Dullaart RP, Groen AK, Dallinga-Thie GM, de Vries R, Sluiter WJ, van Tol A. 
Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective 
despite low high-density lipoprotein cholesterol. Eur J Endocrinol. 2008;158(1):53-60. 
19. Borja MS, Hammerson B, Tang C, Savinova OV, Shearer GC, Oda MN. Apolipoprotein 
A-I exchange is impaired in metabolic syndrome patients asymptomatic for diabetes and 
cardiovascular disease. PLoS One. 2017;12(8):e0182217. 
20. Annema W, Dikkers A, de Boer JF, et al. Impaired HDL cholesterol efflux in metabolic 
syndrome is unrelated to glucose tolerance status: The CODAM study. Sci Rep. 
2016;6:27367. 
 
37 
 
21. Roe A, Hillman J, Butts S, et al. Decreased cholesterol efflux capacity and atherogenic 
lipid profile in young women with PCOS. J Clin Endocrinol Metab. 2014;99(5):E841-7. 
22. Sankaranarayanan S, Kellner-Weibel G, de la Llera-Moya M, et al. A sensitive assay for 
ABCA1-mediated cholesterol efflux using BODIPY-cholesterol. J Lipid Res. 
2011;52(12):2332-2340. 
23. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident 
cardiovascular events. N Engl J Med. 2014;371(25):2383-2393. 
24. Liu C, Zhang Y, Ding D, et al. Cholesterol efflux capacity is an independent predictor of 
all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective 
cohort study. Atherosclerosis. 2016;249:116-124. 
25. Ishikawa T, Ayaori M, Uto-Kondo H, Nakajima T, Mutoh M, Ikewaki K. High-density 
lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary 
disease. Atherosclerosis. 2015;242(1):318-322. 
26. Saleheen D, Scott R, Javad S, et al. Association of HDL cholesterol efflux capacity with 
incident coronary heart disease events: A prospective case-control study. Lancet Diabetes 
Endocrinol. 2015;3(7):507-513. 
27. Shea S, Stein JH, Jorgensen NW, et al. Cholesterol mass efflux capacity, incident 
cardiovascular disease, and progression of carotid plaque. Arterioscler Thromb Vasc Biol. 
2019;39(1):89-96. 
 
38 
 
28. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-
density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127-135. 
29. Khera AV, Demler OV, Adelman SJ, et al. Cholesterol efflux capacity, high-density 
lipoprotein particle number, and incident cardiovascular events: An analysis from the 
JUPITER trial (justification for the use of statins in prevention: An intervention trial 
evaluating rosuvastatin). Circulation. 2017;135(25):2494-2504. 
30. Ogura M, Hori M, Harada-Shiba M. Association between cholesterol efflux capacity and 
atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia. 
Arterioscler Thromb Vasc Biol. 2016;36(1):181-188. 
31. Victor RG, Haley RW, Willett DL, et al. The dallas heart study: A population-based 
probability sample for the multidisciplinary study of ethnic differences in cardiovascular 
health. Am J Cardiol. 2004;93(12):1473-1480. 
32. Lakoski SG, Kozlitina J. Ethnic differences in physical activity and metabolic risk: The 
dallas heart study. Med Sci Sports Exerc. 2014;46(6):1124-1132. 
33. Yancey PG, Kawashiri MA, Moore R, et al. In vivo modulation of HDL phospholipid has 
opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux. J Lipid Res. 
2004;45(2):337-346. 
34. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint 
interim statement of the international diabetes federation task force on epidemiology and 
 
39 
 
prevention; national heart, lung, and blood institute; american heart association; world heart 
federation; international atherosclerosis society; and international association for the study of 
obesity. Circulation. 2009;120(16):1640-1645. 
35. Alenezi MY, Marcil M, Blank D, Sherman M, Genest J,Jr. Is the decreased high-density 
lipoprotein cholesterol in the metabolic syndrome due to cellular lipid efflux defect? J Clin 
Endocrinol Metab. 2004;89(2):761-764. 
  
 
 
 
 
